NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.

ABSTRACT:

Background

There are no validated tools for the clinical neurological assessment of patients with leptomeningeal metastases (LM). However, clinical examination during the course of the disease guides medical management and is part of response assessment in clinical trials. Because neuroimaging may not always be obtained owing to rapid clinical deterioration, clinical neurological assessment of LM is essential, and standardization is important to minimize rater disagreement.

Methods

The Response Assessment in Neuro-oncology-LM group launched a 2-step process, aiming at improving and standardizing the clinical assessment of patients with LM. We report here on the first step the establishment of a consensus scorecard. The task force had 9 virtual meetings to define general reco

SUBMITTER: Le Rhun E 

PROVIDER: S-EPMC11812256 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature